EGFR and non-small cell lung carcinoma: Compared to the single drug treatment, the combination of EGFR-TKI and atorvastatin have a greater tumor suppressive effect in non-small cell lung cancer, suggesting that the combination medicine (statin and TKI) has the potential to be a novel therapy for EGFR-mutant non-small cell lung cancer (Fig. 4).67